Inhibikase Therapeutics, Inc. announced that it has developed a novel tablet formulation of IkT-148009, designed to improve drug exposure and overcome existing challenges related to patient use.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
1.264 USD | +4.50% | -4.92% | -0.43% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-0.43% | 8.73M | |
+22.84% | 45.51B | |
-7.42% | 38.52B | |
+38.85% | 38.13B | |
+26.79% | 30.74B | |
-13.50% | 26.03B | |
+13.25% | 25.92B | |
+45.49% | 14.13B | |
+35.23% | 12.73B | |
-5.47% | 11.29B |
- Stock Market
- Equities
- IKT Stock
- News Inhibikase Therapeutics, Inc.
- Inhibikase Therapeutics, Inc. Announces Development of Novel Formulation of Rampsvodetinib